Figure 2.
Afu-specific IgE and IgG antibody levels in sera after 10th day of prophylactic (A) and therapeutic (B) treatment with PBS or Asp f1 peptides P1-P3. Each regimen had 5 groups of mice: Non-challenged control, PBS-treated Afu-challenged (prophylactic) or ABPA (therapeutic), P1-treated, P2-treated and P3-treated mice. Data represents O.D. at 492 nm and error bars indicate the mean±SD of triplicate determinations with five mice per group, *p<0.05 versus PBS-treated ABPA/Afu challenged mice.